Markets

The 3 Top Performing Biotech Stocks That Debuted in 2015

A list of stock prices rising and declining in value
Credit: Shutterstock photo

The year of 2015 was an up and down ride for companies that launched initial public offerings (IPOs) as the stock market as a whole failed to produce consistent large gains. One sector, however, saw a great deal of success in the IPO area: biotechnology stocks. Biotechnology IPOs actually make up a great deal of the list of top performing IPOs across all sectors. Below are the top 3 performing biotech stocks since their 2015 market debut.

Collegium Pharmaceuticals (COLL)

Coming in at the third on the list is Collegium Pharmaceuticals COLL , a specialty pharmaceutical company based in Canton, Massachusetts that focuses on developing and commercializing abuse-deterrent products for the treatment of chronic pain and other diseases. The company's IPO was priced in early May of this year, debuting at $12 a share. It now currently trades at around $24 a share, representing an approximate 100% jump in share price since its launch on the NASDAQ.

In most recent news, the company filed an S-1 form with the SEC on December 21 st for a secondary offering, though details regarding how many shares will be offered and when the offering will take place are unknown. The value of the offering according to the filing from COLL, is upwards of $86.25 million. COLL currently holds a Zacks Rank #3 (Hold) at the moment.

Seres Therapeutics (MCRB)

At second on the list is Cambridge, Massachusetts-based Seres Therapeutics, Inc. MCRB , that focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company debuted in late June with a share price of $18 per share. Currently MCRB trades at over $38 a share, representing a gain of over 112% since its initial offering.

MCRB currently holds a Zacks Rank #3 (Hold), though that ranking could change in the near future if the company's new trial in ulcerative colitis performs well in the coming months.

Aclaris Therapeutics Inc. (ACRS)

Finally, the company with the best performing stock since its IPO in 2015 is Aclaris Therapeutics Inc. ACRS . Based in Malvern, Pennsylvania, ACRS is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology.

Aclaris launched its IPO not too long ago in October, offering 5 million shares for $11 a share. The company's stock now trades around $29 a share, which represents an approximate 167% gain since its debut. ACRS also holds a Zacks Rank #3 (Hold), but that could change as the company continues different drug trials in the coming months.

Bottom Line

The biotech industry is currently one of the higher ranked industries across the board, ranked in the top 20%, and as 2015 comes to an end, it seems as though it will finish the year as one of the better performing industries too. The stocks above have all performed extremely well since their initial public offerings, and their futures hold great potential moving forward. Though all 3 companies currently have Zacks Rank #3's (Holds), one major breakthrough during the clinical trials of a drugs or treatment could potentially send each respective company's stock skyrocketing. While 2015 was a great year performance-wise, investors should keep their eyes on Collegium Pharmaceuticals, Seres Therapeutics, and Aclaris Therapeutics as we move forward into 2016.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

COLLEGIUM PHARM (COLL): Free Stock Analysis Report

SERES THERAPEUT (MCRB): Free Stock Analysis Report

ACLARIS THERAPT (ACRS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

COLL MCRB ACRS

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More